ClinicalTrials.gg
CompletedNCT02795039Updated Mar 9, 2017

Bioequivalence Study of Fulvestrant Injection 50 mg/mL in Healthy Post-menopausal Female Subjects

A Phase 1 interventional study of Fulvestrant and Fulvestrant in Healthy, sponsored by Fresenius Kabi. Completed at 3 sites in Canada. Open to female participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-09.

Sponsored by Fresenius Kabi · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
266
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Study summary

The purpose of this study is to demonstrate bioequivalence between the test drug product, fulvestrant Injection, 50 mg/mL, and the Reference Listed Drug, Faslodex® Injection, 50 mg/mL.

Read the detailed description

This study is being conducted to establish bioequivalence between sponsor's test product [fulvestrant Injection, 50 mg/mL (Manufactured for Fresenius Kabi, USA)] and reference listed drug [Faslodex® Injection, 50 mg/mL, (Distributed by AstraZeneca Pharmaceuticals, USA] after intramuscular administration of a 250 mg dose (5 mL injection) into the upper outer quadrant of the right buttock to normal, healthy, nonsmoking post-menopausal female subjects.

The order of receiving the test product (T) or reference listed drug (R) for each subject during the study will be determined according to a randomization schedule.

Subjects will be allocated with a ratio of 1:1 to both treatment groups (i.e. T and R).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Fresenius Kabi is the lead sponsor of 51 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Normal, healthy, non smoking female subjects between the ages of 40 and 65 years (inclusive) Note: Postmenopausal is defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL. The amenorrhea should not be due to lactation
  • (BMI = weight/height2) greater than or equal to 18.5 kg/m2 and less than or equal to 29.9 kg/m2
  • Physical examination, 12-lead (ECG) and vital signs without any findings
  • Negative for urine drugs of abuse screen, urine nicotine (cotinine) screen, and breath alcohol screen.
  • Negative for -surface antigen, and (HIV)
  • Clinical laboratory values within the acceptable range, unless deemed clinically not significant by the principal investigator or sub-investigator.
  • Availability of the subject for the entire study period and willingness of the subject to adhere to protocol requirements as evidenced by signing the Form (ICF).

Exclusion criteria

Exclusion Criteria:

  • History of gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, musculoskeletal, psychiatric, or cardiovascular disease or or any other condition which, in the opinion of the principal investigator or sub-investigator, would jeopardize the safety of the subject or impact the validity of the study results.
  • A history of allergic or adverse response(s) to fulvestrant, castor oil, benzyl alcohol, benzyl benzoate, polysorbate 80, α-tocopherol or any other comparable or similar products.
  • Smoking or use of tobacco products within 6 months prior to the first dose of study drug or during the study
  • Positive urine pregnancy test at screening or serum pregnancy test prior to administration of study drug.
  • History of any bleeding disorders
  • Consumption of alcohol exceeding 10 drinks/ week in the previous 1 year
  • Intolerance to/fear of venipuncture, needles or blood draws
  • Have consumed any products or undergone any procedures mentioned under "restriction table" in protocol
  • Surgically-induced post menopausal females
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
266 participants (actual)

Study arms

  • Experimental
    Fulvestrant 50mg/mL (Fresenius Kabi)

    5 mL intramuscular injection

    Drug: Fulvestrant

  • Active comparator
    Fulvestrant 50 mg/mL (Faslodex®)

    5 mL intramuscular injection

    Drug: Fulvestrant

Interventions

  • Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Fulvestrant into the right buttock (upper outer quadrant)

  • Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Faslodex® (Fulvestrant) into the right buttock (upper outer quadrant)

    Also known as: Faslodex

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration

    Time frame: 0-238 days

  2. Area under the plasma concentration versus time curve (AUC0-238d) of fulvestrant

    Time frame: 0-238 days

Secondary outcomes

  1. Area under the plasma concentration versus time curve (AUC0-28d) of fulvestrant

    Time frame: 0-28 day

  2. Area under the plasma concentration versus time curve from time zero to the last measurable concentration (AUC0-t)

    Time frame: 0-238 days

  3. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC0-∞)

    Time frame: 0-238 days

  4. Time to Reach the Maximum Plasma Concentration (Tmax)

    Time frame: 0-238 days

  5. Elimination Half-life Period (t1/2)

    Time frame: 0-238 days

  6. Terminal Slope (λz)

    Time frame: 0-238 days

  7. Residual area in percentage (AUC_%Extrap_obs)

    Time frame: 0-238 days

  8. Injection site pain assessment

    Time frame: 0-8 days

07

Study locations

3 sites
  • Lambda Therapeutic Research Inc.
    Toronto, Ontario M1L4S4, Canada
  • BioPharma Services Inc.
    Toronto, Ontario M9L 3A2, Canada
  • Algorithme Pharma Inc.
    Mount Royal, Quebec H3P 3P1, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016, a primary completion of Mar 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2016
First posted
Jun 9, 2016
Start
Jun 2016
Primary completionActual
Mar 3, 2017
CompletionActual
Mar 3, 2017
Last update
Mar 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02795039
Lead sponsor
Fresenius Kabi
Responsible party
Sponsor
First posted
Jun 9, 2016
Start date
Jun 2016
Primary completion
Mar 3, 2017
Completion
Mar 3, 2017
Last update
Mar 9, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion